|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
US4810646A
(en)
|
1984-11-28 |
1989-03-07 |
Massachusetts Institute Of Technology |
Glucan compositions and process for preparation thereof
|
|
US5082936A
(en)
|
1984-11-28 |
1992-01-21 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US5028703A
(en)
|
1988-03-11 |
1991-07-02 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US4992540A
(en)
|
1984-11-28 |
1991-02-12 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
DE3529497A1
(de)
|
1985-08-17 |
1987-02-26 |
Boehringer Mannheim Gmbh |
N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
US5750666A
(en)
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
|
AU650626B2
(en)
|
1989-09-08 |
1994-06-30 |
Alpha-Beta Technology, Inc. |
Method for producing soluble glucans
|
|
ES2103276T3
(es)
|
1989-09-08 |
1997-09-16 |
Alpha Beta Technology |
Composicion para la activacion del sistema inmunitario.
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
EP0497875B1
(en)
|
1989-10-24 |
2000-03-22 |
Isis Pharmaceuticals, Inc. |
2' modified oligonucleotides
|
|
US5495009A
(en)
|
1989-10-24 |
1996-02-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs containing thioformacetal linkages
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
WO1992003568A1
(en)
|
1990-08-13 |
1992-03-05 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5514786A
(en)
|
1990-01-11 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Compositions for inhibiting RNA activity
|
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5658731A
(en)
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
|
CA2040374C
(en)
|
1990-07-06 |
1998-06-16 |
Gunnar Rorstad |
Process for enhancing the resistance of aquatic animals to disease
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
CA2088258C
(en)
|
1990-07-27 |
2004-09-14 |
Phillip Dan Cook |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
JP3256539B2
(ja)
|
1990-08-28 |
2002-02-12 |
エポック・ファーマシューティカルズ・インコーポレイテッド |
連結分子を介する３’―尾分子付オリゴヌクレオチドの固体支持体合成
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
AU662298B2
(en)
|
1990-09-20 |
1995-08-31 |
Gilead Sciences, Inc. |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
GB9022560D0
(en)
|
1990-10-17 |
1990-11-28 |
G B Biotechnology Limited |
Processing of waste
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
US5419966A
(en)
|
1991-06-10 |
1995-05-30 |
Microprobe Corporation |
Solid support for synthesis of 3'-tailed oligonucleotides
|
|
US7384634B2
(en)
|
1991-08-30 |
2008-06-10 |
University Of South Florida |
Connective tissue growth factor
|
|
US5770209A
(en)
|
1991-08-30 |
1998-06-23 |
University Of South Florida |
Acceleration of wound healing using connective tissue growth factor
|
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US5856455A
(en)
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
|
NZ245720A
(en)
|
1992-01-22 |
1995-12-21 |
Hoechst Ag |
Oligonucleotide analogues; use as gene expression inhibitor or dna probe
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
EP0693123A1
(en)
|
1993-03-31 |
1996-01-24 |
HYBRIDON, Inc. |
Modified oligonucleotides having improved anti-influenza activity
|
|
JPH08508491A
(ja)
|
1993-03-31 |
1996-09-10 |
スターリング ウインスロップ インコーポレイティド |
ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
DK0626387T3
(da)
|
1993-05-12 |
1999-09-27 |
Novartis Ag |
Nukleosider og oligonukleotider med 2'-ethergrupper
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5532130A
(en)
|
1993-07-20 |
1996-07-02 |
Dyad Pharmaceutical Corporation |
Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5614621A
(en)
|
1993-07-29 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
|
|
EP0748382B1
(en)
|
1993-09-02 |
2002-11-06 |
Ribozyme Pharmaceuticals, Inc. |
Non-nucleotide containing enzymatic nucleic acid
|
|
EP0728139B1
(en)
|
1993-09-03 |
2003-08-13 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
JPH09504297A
(ja)
|
1993-10-27 |
1997-04-28 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
２′−アミドおよび２′−ペプチド修飾オリゴヌクレオチド
|
|
WO1995013833A1
(en)
|
1993-11-16 |
1995-05-26 |
Genta Incorporated |
Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
|
|
US20030130324A1
(en)
|
1993-11-19 |
2003-07-10 |
Johnston W. Mcavoy |
Method for preventing or controlling cataract
|
|
US5652359A
(en)
|
1993-12-02 |
1997-07-29 |
Epoch Pharmaceuticals, Inc. |
Oligonucleotides containing n-methyl thiolated bases having antiviral activity
|
|
EP0796109A1
(en)
|
1993-12-17 |
1997-09-24 |
The Ohio State University |
Antisense oligonucleotides to suppress eicosanoid formation
|
|
AU1878895A
(en)
|
1994-02-18 |
1995-09-04 |
Hybridon, Inc. |
Oligonucleotides with anti-respiratory syncytial virus activity
|
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
|
US5948767A
(en)
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
|
US5716824A
(en)
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
|
US6221911B1
(en)
|
1995-06-07 |
2001-04-24 |
Karo Bio Ab |
Uses for thyroid hormone compounds or thyroid hormone-like compounds
|
|
US5736392A
(en)
|
1995-06-07 |
1998-04-07 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
|
EP0832271B8
(en)
|
1995-06-07 |
2005-03-02 |
INEX Pharmaceuticals Corp. |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
AUPN398295A0
(en)
|
1995-07-05 |
1995-07-27 |
Carlton And United Breweries Limited |
Chemical compounds and processes for their production
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US5705621A
(en)
|
1995-11-17 |
1998-01-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
|
|
US5684143A
(en)
|
1996-02-21 |
1997-11-04 |
Lynx Therapeutics, Inc. |
Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
|
|
US6331617B1
(en)
|
1996-03-21 |
2001-12-18 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
|
US6444806B1
(en)
|
1996-04-30 |
2002-09-03 |
Hisamitsu Pharmaceutical Co., Inc. |
Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
|
US6111085A
(en)
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
|
US7504493B2
(en)
|
1997-01-23 |
2009-03-17 |
The John Hopkins University |
Characterization of the yeast transcriptome
|
|
JP4656675B2
(ja)
|
1997-05-14 |
2011-03-23 |
ユニバーシティー オブ ブリティッシュ コロンビア |
脂質小胞への荷電した治療剤の高率封入
|
|
US6333152B1
(en)
|
1997-05-21 |
2001-12-25 |
The Johnshopkins University |
Gene expression profiles in normal and cancer cells
|
|
ATE347911T1
(de)
|
1997-09-15 |
2007-01-15 |
Genetic Immunity Llc |
Zusammensetzungen für die zufuhr von genen an antigen-präsentierende zellen der haut
|
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
|
AU1507199A
(en)
|
1997-12-15 |
1999-07-05 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel pyrimidine-5-carboxamide derivatives
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
EP1043335A4
(en)
|
1997-12-25 |
2005-08-31 |
Japan Tobacco Inc |
MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
|
|
US6020475A
(en)
|
1998-02-10 |
2000-02-01 |
Isis Pharmeuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
WO1999054459A2
(en)
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
US20040241845A1
(en)
|
1998-05-22 |
2004-12-02 |
Luc Desgroseillers |
Mammalian staufen and use thereof
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
US20040009938A1
(en)
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
|
US6344323B1
(en)
*
|
1998-09-16 |
2002-02-05 |
Vitagenix, Inc. |
Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
|
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
|
US6475490B1
(en)
|
1998-10-19 |
2002-11-05 |
Fordham University |
Compositions and methods for promoting tissue repair using heat shock proteins
|
|
US7115390B1
(en)
|
1998-12-14 |
2006-10-03 |
Fibrogen, Inc. |
Connective tissue growth factor fragments and methods and uses thereof
|
|
PT1140969E
(pt)
|
1998-12-14 |
2007-08-30 |
Univ Miami |
Fragmentos do factor de crescimento de tecido conectivo e os seus métodos e utilizações
|
|
US6455586B1
(en)
|
1998-12-15 |
2002-09-24 |
Leonard L. Kaplan |
Topical immunomodulating compositions for treatment of aids, Hepatitis B & C, other infectious diseases, and cancer
|
|
DK1621212T3
(da)
|
1999-01-27 |
2012-03-05 |
Coda Therapeutics Inc |
Formuleringer omfattende antisense-nukleotider til connexiner
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
|
ES2234563T5
(es)
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US6706491B1
(en)
|
1999-04-09 |
2004-03-16 |
The Board Of Trustees Of The University Of Illinois |
Reagents and methods for identifying and modulating expression of genes regulated by p21
|
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
CA2378512A1
(en)
|
1999-06-16 |
2000-12-21 |
The Johns Hopkins University |
Characterization of the yeast transcriptome
|
|
US6593466B1
(en)
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
|
US8017742B2
(en)
|
1999-11-10 |
2011-09-13 |
Japan Science And Technology Agency |
Gene carrier
|
|
JP2001206899A
(ja)
|
1999-11-18 |
2001-07-31 |
Japan Tobacco Inc |
ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
|
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
IL151781A0
(en)
|
2000-03-16 |
2003-04-10 |
Genetica Inc |
Methods and compositions for rna interference
|
|
IL151928A0
(en)
|
2000-03-30 |
2003-04-10 |
Whitehead Biomedical Inst |
Rna sequence-specific mediators of rna interference
|
|
US7108721B2
(en)
|
2000-05-11 |
2006-09-19 |
Massachusetts Institute Of Technology |
Tissue regrafting
|
|
JP2004500846A
(ja)
|
2000-05-11 |
2004-01-15 |
アカデミス ジーケンホイス ベイ デ ユニフェルジテイト ファン アムステルダム |
Ｍｙｃ標的
|
|
US7175844B2
(en)
|
2000-07-18 |
2007-02-13 |
Joslin Diabetes Center, Inc. |
Methods of modulating fibrosis
|
|
WO2002008205A1
(en)
|
2000-07-24 |
2002-01-31 |
Krenitsky Pharmaceuticals, Inc. |
Substituted 5-alkynyl pyrimidines having neurotrophic activity
|
|
EP1307557A2
(en)
|
2000-08-02 |
2003-05-07 |
The Johns Hopkins University |
Endothelial cell expression patterns
|
|
AU2001279796A1
(en)
|
2000-08-03 |
2002-02-18 |
Abac R & D Gmbh |
Isolation of glucan particles and uses thereof
|
|
US6794137B2
(en)
|
2000-09-08 |
2004-09-21 |
New York University |
Gene markers useful for detecting skin damage in response to ultraviolet radiation
|
|
AU2001291019A1
(en)
|
2000-09-15 |
2002-03-26 |
Genvec, Inc. |
Method of modulating neovascularization
|
|
US6476003B1
(en)
|
2000-11-06 |
2002-11-05 |
Immusonic, Inc. |
Method for preparing small particle size glucan in a dry material
|
|
US20020132788A1
(en)
|
2000-11-06 |
2002-09-19 |
David Lewis |
Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
|
|
BRPI0115814B8
(pt)
|
2000-12-01 |
2021-05-25 |
Europaeisches Laboratorium Fuer Molekularbiologie Embl |
moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
|
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
|
JP2004532616A
(ja)
|
2000-12-28 |
2004-10-28 |
ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド |
二本鎖ｒｎａ仲介遺伝子抑制
|
|
DE10100121A1
(de)
|
2001-01-03 |
2002-08-01 |
Henkel Kgaa |
Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
|
|
DE10100127A1
(de)
|
2001-01-03 |
2002-10-02 |
Henkel Kgaa |
Verfahren zur Bestimmung der Homeostase der Haut
|
|
US7044945B2
(en)
|
2001-03-30 |
2006-05-16 |
Sand Bruce J |
Prevention of regression in thermal ciliary muscle tendinoplasty
|
|
US7393932B2
(en)
|
2001-04-11 |
2008-07-01 |
The Johns Hopkins University |
Endothelial cell expression patterns
|
|
US20030077829A1
(en)
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
|
US20050233997A1
(en)
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
|
EP1627061B1
(en)
|
2001-05-18 |
2009-08-12 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20060211642A1
(en)
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
|
US20070032441A1
(en)
|
2001-05-18 |
2007-02-08 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
|
DE10131458A1
(de)
|
2001-06-29 |
2003-01-09 |
Aventis Pharma Gmbh |
Verfahren zur Identifizierung von Verbindungen zur Therapie von Alterungsprozessen des Herz-Kreislauf Systems
|
|
US20030158403A1
(en)
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
|
WO2003012052A2
(en)
|
2001-07-30 |
2003-02-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Specific inhibition of gene expression by small double stranded rnas
|
|
AU2002326939A1
(en)
*
|
2001-09-18 |
2003-04-01 |
Fibrogen, Inc. |
Methods of assaying connective tissue growth factor
|
|
US7786094B2
(en)
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
|
WO2003035083A1
(de)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
|
|
US20040248835A1
(en)
|
2001-10-26 |
2004-12-09 |
Anja Krebs |
Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
|
|
EP1575976A4
(en)
|
2001-11-02 |
2006-08-23 |
Insert Therapeutics Inc |
METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
JP2005519881A
(ja)
|
2001-12-11 |
2005-07-07 |
ファイブローゲン、インコーポレーテッド |
眼プロセスの抑制方法
|
|
EP1470144B1
(en)
|
2002-02-01 |
2008-12-03 |
McGILL UNIVERSITY |
Oligonucleotides comprising alternating segments and uses thereof
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
|
US20040014956A1
(en)
|
2002-02-01 |
2004-01-22 |
Sequitur, Inc. |
Double-stranded oligonucleotides
|
|
AU2003216255A1
(en)
|
2002-02-20 |
2003-09-09 |
Ribozyme Pharmaceuticals, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US6923833B2
(en)
|
2002-04-09 |
2005-08-02 |
Ray C. Wasielewski |
Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function
|
|
AU2003237249A1
(en)
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
FR2840217B1
(fr)
|
2002-06-03 |
2005-06-24 |
Oreal |
Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
|
|
US20040005262A1
(en)
*
|
2002-06-05 |
2004-01-08 |
Exxonmobil Research And Engineering Company |
Process for reducing NOx in waste gas streams using chlorine dioxide
|
|
EP3222725A1
(en)
|
2002-08-05 |
2017-09-27 |
Silence Therapeutics GmbH |
Further novel forms of interfering rna molecules
|
|
DE10238298A1
(de)
|
2002-08-21 |
2004-03-04 |
Beiersdorf Ag |
Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
|
|
EP1546344A4
(en)
|
2002-09-18 |
2007-10-03 |
Isis Pharmaceuticals Inc |
EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS
|
|
CA2881743A1
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
US20060035344A1
(en)
|
2002-10-18 |
2006-02-16 |
Pachuk Catherine J |
Double-stranded rna structures and constructs, and methods for generating and using the same
|
|
US7309361B2
(en)
|
2002-10-23 |
2007-12-18 |
Wasielewski Ray C |
Biologic modular tibial and femoral component augments for use with total knee arthroplasty
|
|
JP2006517916A
(ja)
|
2002-10-30 |
2006-08-03 |
ザ シービーアール インスティテュート フォー バイオメディカル リサーチ インコーポレーティッド |
Ｒｎａ干渉物質を用いてアポトーシス関連疾患を治療および予防する方法
|
|
ATE443764T1
(de)
|
2002-11-04 |
2009-10-15 |
Univ Massachusetts |
Allelspezifische rna-interferenz
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP2314691A3
(en)
|
2002-11-14 |
2012-01-18 |
Dharmacon, Inc. |
Fuctional and hyperfunctional siRNA
|
|
DE10254214A1
(de)
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
|
EP1585756B1
(en)
|
2002-11-26 |
2010-04-21 |
University of Massachusetts |
Delivery of sirnas
|
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
|
WO2004065600A2
(en)
|
2003-01-17 |
2004-08-05 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference by palindromic or modified rna molecules
|
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
|
CA2514912A1
(en)
|
2003-02-05 |
2004-08-26 |
University Of Massachusetts |
Rnai targeting of viruses
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
US20040167090A1
(en)
|
2003-02-21 |
2004-08-26 |
Monahan Sean D. |
Covalent modification of RNA for in vitro and in vivo delivery
|
|
EP1604012A2
(en)
|
2003-03-05 |
2005-12-14 |
The Board of Trustees of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
|
|
EP2239329A1
(en)
|
2003-03-07 |
2010-10-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
WO2004085621A2
(en)
|
2003-03-20 |
2004-10-07 |
Dana-Farber Cancer Institute, Inc. |
Gene expression in breast cancer
|
|
JP4605799B2
(ja)
|
2003-04-02 |
2011-01-05 |
ダーマコン， インコーポレイテッド |
Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
|
|
EP2660322A3
(en)
|
2003-04-17 |
2013-11-13 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
|
US7462602B2
(en)
|
2003-05-01 |
2008-12-09 |
University Of Florida Research Foundation, Inc. |
Anti-scarring ribozymes and methods
|
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
EP1633890B2
(en)
|
2003-06-02 |
2020-11-18 |
University of Massachusetts |
METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
|
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
|
US7786290B2
(en)
|
2003-06-13 |
2010-08-31 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
EP1648519B1
(en)
|
2003-07-16 |
2014-10-08 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
WO2005019430A2
(en)
|
2003-08-22 |
2005-03-03 |
Research Development Foundation |
In vitro selection of aptamer beacons
|
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
|
EP1687410A4
(en)
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
|
|
EP1692154A4
(en)
|
2003-11-24 |
2009-07-08 |
Canji Inc |
REDUCTION OF SKIN TEMPERING
|
|
AU2004299670B2
(en)
*
|
2003-12-19 |
2010-04-22 |
Antisense Pharma Gmbh |
Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
|
|
US20080254487A1
(en)
|
2004-01-16 |
2008-10-16 |
Fibrogen, Inc. |
Connective Tissue Growth Factor Signaling
|
|
EP2123759B1
(en)
|
2004-02-06 |
2014-01-15 |
Thermo Fisher Scientific Biosciences Inc. |
Stabilized RNAS as transfection controls and silencing reagents
|
|
WO2005079533A2
(en)
|
2004-02-17 |
2005-09-01 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
WO2005080582A1
(ja)
|
2004-02-20 |
2005-09-01 |
National Institute Of Advanced Industrial Science And Technology |
細胞質局在化ｄｎａ及びｒｎａ
|
|
US20060058255A1
(en)
|
2004-03-01 |
2006-03-16 |
Jianzhu Chen |
RNAi-based therapeutics for allergic rhinitis and asthma
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
WO2005098041A2
(en)
|
2004-03-26 |
2005-10-20 |
University Of Florida Research Foundation, Inc. |
Detection and treatment of fibrotic disorders
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
|
JP4635046B2
(ja)
|
2004-04-20 |
2011-02-16 |
マリナ・バイオテック・インコーポレーテッド |
哺乳類の細胞における遺伝子発現を調節するための、二本鎖ｒｎａまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物
|
|
US8168600B2
(en)
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
|
MXPA06013420A
(es)
|
2004-05-20 |
2007-03-01 |
Eden Research Plc |
Composiciones que contienen una particula hueca de glucano o una particula de pared celular que encapsula un componente de terpeno, metodos para elaborar y usar las mismas.
|
|
EP1765416A4
(en)
|
2004-06-03 |
2010-03-24 |
Isis Pharmaceuticals Inc |
DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION
|
|
EP1766035B1
(en)
|
2004-06-07 |
2011-12-07 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering rna
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
CN105251024A
(zh)
|
2004-08-23 |
2016-01-20 |
西伦蒂斯私人股份公司 |
眼病的治疗
|
|
US20060211766A1
(en)
|
2004-09-30 |
2006-09-21 |
Kaplan Leonard L |
Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections
|
|
WO2006039656A2
(en)
|
2004-10-01 |
2006-04-13 |
Novartis Vaccines And Diagnostics Inc. |
Modified small interfering rna molecules and methods of use
|
|
US20100069620A1
(en)
|
2004-12-02 |
2010-03-18 |
Rxi Pharmaceuticals Corp. |
Novel compositions of chemically modified small interfering rna
|
|
WO2006065601A2
(en)
|
2004-12-15 |
2006-06-22 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
TWI386225B
(zh)
*
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
US20060171943A1
(en)
|
2005-02-01 |
2006-08-03 |
Amgen Inc. |
Compositions and methods of treating fibrotic disorders
|
|
EP1891217A2
(en)
|
2005-05-27 |
2008-02-27 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina)
|
|
WO2007030167A1
(en)
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
|
JP5489462B2
(ja)
|
2005-10-24 |
2014-05-14 |
ユニバーシティ オブ マサチューセッツ |
骨病状の遺伝子治療のための組成物およびそれらの使用法
|
|
WO2007056440A1
(en)
|
2005-11-07 |
2007-05-18 |
Titan Pharmaceuticals, Inc. |
Treatment and prevention of adverse liver conditions using gallium
|
|
FR2894582B1
(fr)
|
2005-12-12 |
2008-02-22 |
Fabre Pierre Dermo Cosmetique |
Sirna anti myosine va et depigmentation de la peau
|
|
JP2009519033A
(ja)
*
|
2005-12-16 |
2009-05-14 |
ディアト |
核酸を細胞に送達するための細胞貫通ペプチド結合体
|
|
CN101426914A
(zh)
|
2005-12-30 |
2009-05-06 |
因特拉迪格姆公司 |
促进皮肤的无疤痕伤口痊愈的siRNA组合物以及用于伤口治疗的方法
|
|
CN101374528A
(zh)
*
|
2006-01-20 |
2009-02-25 |
夸克医药公司 |
Rtp801的治疗用途
|
|
US7825099B2
(en)
*
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
EP1981543A1
(en)
|
2006-01-23 |
2008-10-22 |
Abbott Laboratories |
Chemically modified polycation polymer for sirna delivery
|
|
CA2638906A1
(en)
|
2006-01-26 |
2007-08-16 |
University Of Massachusetts |
Rna interference agents for therapeutic use
|
|
US20100286233A1
(en)
|
2006-03-09 |
2010-11-11 |
University Of Rochester |
Peripheral and neural inflammatory crosstalk
|
|
ES2569558T3
(es)
|
2006-04-03 |
2016-05-11 |
Roche Innovation Center Copenhagen A/S |
Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
|
|
DK2363481T3
(en)
|
2006-05-05 |
2017-06-26 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating gene expression
|
|
CA2658058C
(en)
|
2006-06-23 |
2016-08-23 |
Engeneic Molecular Delivery Pty Ltd. |
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
|
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
|
EP2061443A4
(en)
|
2006-08-18 |
2013-07-24 |
Arrowhead Res Corp |
POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES
|
|
EP2081949B1
(en)
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
US20080193443A1
(en)
|
2006-10-30 |
2008-08-14 |
Oxana Beskrovnaya |
Methods and compositions for the treatment of polycystic diseases
|
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
|
US20090010948A1
(en)
|
2006-12-15 |
2009-01-08 |
The University Of Hong Kong |
Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
|
|
WO2008109353A1
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting map2k gene expression and uses thereof
|
|
US20080311040A1
(en)
|
2007-03-06 |
2008-12-18 |
Flagship Ventures |
METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
|
|
JP2010532360A
(ja)
|
2007-07-02 |
2010-10-07 |
ワイス・エルエルシー |
骨障害の処置における使用のためのａｘｌのモジュレーター
|
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
US20090043367A1
(en)
|
2007-08-09 |
2009-02-12 |
Yitzhak Zilberman |
Apparatus and methods for removing an electronic implant from a body
|
|
CA2697043A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Virginia Commonwealth University Intellectual Property Foundation |
Methods and compositions for treatment or prevention of radiation-induced fibrosis
|
|
ES2873350T3
(es)
|
2007-08-27 |
2021-11-03 |
1Globe Health Inst Llc |
Composiciones de ARN interferente asimétrico y usos de las mismas
|
|
JP5296081B2
(ja)
*
|
2007-10-02 |
2013-09-25 |
テレフオンアクチーボラゲット エル エム エリクソン（パブル） |
通信システムの方法及び装置
|
|
CA2702028A1
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
EP2231168A4
(en)
|
2007-10-03 |
2012-01-04 |
Quark Pharmaceuticals Inc |
NEW STRUCTURES OF ARNSI
|
|
EP3156077B1
(en)
|
2007-12-04 |
2022-03-09 |
Arbutus Biopharma Corporation |
Targeting lipids
|
|
KR100949791B1
(ko)
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
EP2245039A4
(en)
|
2008-01-31 |
2012-06-06 |
Alnylam Pharmaceuticals Inc |
OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
|
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
|
US20110218334A1
(en)
|
2008-07-11 |
2011-09-08 |
Alnylam Pharmaceuticals, Inc. |
PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
|
|
AU2009272841A1
(en)
*
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of TGF-beta receptor genes
|
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
|
EP2318528A1
(en)
|
2008-07-24 |
2011-05-11 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
DK2331141T3
(en)
|
2008-08-25 |
2016-04-04 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
|
|
US8946172B2
(en)
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
|
WO2010027832A1
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
WO2010027830A2
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
|
|
WO2010033247A2
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
|
EP2346883B1
(en)
|
2008-09-23 |
2016-03-23 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
|
EP3584320A1
(en)
*
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
WO2010151640A2
(en)
|
2009-06-24 |
2010-12-29 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
|
|
AU2010305284A1
(en)
|
2009-10-06 |
2012-05-03 |
Angiochem Inc. |
Compositions and methods for the transport of therapeutic agents
|
|
WO2011109248A1
(en)
|
2010-03-02 |
2011-09-09 |
Hapten Pharmaceuticals, Llc |
Effective sensitizing dose of a gelled immunomodulating topical composition
|
|
WO2011109698A1
(en)
|
2010-03-04 |
2011-09-09 |
Rxi Pharmaceuticals Corporation |
Formulations and methods for targeted delivery to phagocyte cells
|
|
WO2011119871A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Rna interference in ocular indications
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
|
HUE044178T4
(hu)
|
2011-02-02 |
2019-10-28 |
Excaliard Pharmaceuticals Inc |
Kötõszöveti növekedési faktort (CTGF) célzó antiszensz vegyületek keloidok vagy hipertrófiás hegek kezelési eljárásban történõ alkalmazásra
|
|
US20140072613A1
(en)
|
2012-09-10 |
2014-03-13 |
Cynthia Lander |
Compositions and Methods for Treating Cutaneous Scarring
|
|
CN106061488B
(zh)
|
2013-12-02 |
2021-04-09 |
菲奥医药公司 |
癌症的免疫治疗
|
|
CA2932753A1
(en)
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
JP2017514908A
(ja)
|
2014-05-01 |
2017-06-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
核酸分子を利用する目の前部における障害の処置のための方法
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
US20180263925A1
(en)
|
2014-12-03 |
2018-09-20 |
Rxi Pharmaceuticals Corporation |
Methods for the treatment of alopecia areata utilizing gene modulation approaches
|
|
SI3277815T1
(sl)
|
2015-04-03 |
2022-01-31 |
University Of Massachusetts |
Ologonukleotidne spojine za zdravljenje preeklampsije in drugih angiogeneznih motenj
|
|
EP3766973A1
(en)
|
2015-04-03 |
2021-01-20 |
University Of Massachusetts |
Oligonucleotide compounds for targeting huntingtin mrna
|
|
JP6892433B2
(ja)
|
2015-04-03 |
2021-06-23 |
ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ |
十分に安定化された非対称ｓｉｒｎａ
|
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
CA2997949A1
(en)
|
2015-09-11 |
2017-03-16 |
Rxi Pharmaceuticals Corporation |
Methods for treating skin disorders and conditions utilizing haptens
|
|
WO2017048824A1
(en)
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
|
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SMALL SELF-LEANING NUCLEIC ACID COMPOUNDS TURNED AGAINST LONG NON-CODING RNA
|
|
JP7167059B2
(ja)
|
2017-04-19 |
2022-11-08 |
フィオ ファーマシューティカルズ コーポレーション |
核酸化合物の局所送達
|